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MicroRNA-130a Targets MAP3K12 to Modulate Diabetic Endothelial Progenitor Cell Function
Meng
Introduction
Diabetes mellitus (DM) is associated with various vascular complications and is an important risk factor for cardiovascular diseases. Endothelial dysfunction contributes to the pathogenesis of vascular diseases in diabetes, and endothelial progenitor cell (EPC) plays a critical role in maintaining vascular endothelial function [1] . Bone marrow-derived EPCs migrate to ischemia tissues at the sites of vessel injury and differentiate into mature endothelial cells, where they are involved in the recovery of endothelial function [2] . Hyperglycemia is associated with endothelial dysfunction and is one of the major causes of vascular complications in patients with DM [3] . DM is associated with low levels of circulating EPCs and EPC dysfunction, in particular impaired proliferation, adhesion and migration [4, 5] . Studies have demonstrated that diabetes reduces the number of EPCs and adversely affects the functional capacity of existing EPCs. Therefore, elucidation of the mechanism of DM-induced EPC dysfunction is important to develop effective strategies for the treatment of the complications of DM.
or inhibition of translation [6] . miRNA plays an important role in cell growth, differentiation, and apoptosis. Many miRNAs are involved in the pathogenesis of diabetic complications associated with EPC dysfunction, such as miR-34a, miR-107 and miR-126 [7] [8] [9] . We used microarray analysis technology to screen for miRNAs altered in EPCs derived from type II suggested that miR-130a regulates vascular repair in DM by targeting RunX3, and that it plays an important role in maintaining endothelial cell proliferation, migration and tubulogenic activity [10] . In the present study, we used the Targetscan Program (http//:www. targetscan. org) and predicted MAP3K12 as a novel target of miR-130a in EPCs.
2 -is activated primarily by exposure to environmental stresses, such as osmotic pressure and and apoptosis [13] . Recent genetic evidence and emerging pharmacological data indicate induced by high glucose [5] .
The aim of the present study was to examine the role of miR-130a downregulation in advance our understanding of the role of miRNAs in EPC dysfunction in DM.
Materials and Methods

Patient recruitment
Patients with Type II DM (n=20) were recruited from Shanghai Tenth People's Hospital (Shanghai, China) and 20 mL of blood samples were collected from peripheral veins before treatment. All patients provided written informed consents. Blood samples were collected from healthy individuals (n=20) who presented to the hospital for preventive check-ups and used as normal controls. All protocols were approved by the Research Ethics Board of Shanghai Tenth People's Hospital. Patients' baseline characteristics were
Isolation and cultivation of EPCs
Peripheral human blood (20 mL) was added in 1 mL heparin and separated by Ficoll-Isopaque Plus + cells were incubator, non-adherent cells were removed by washing with phosphate-buffered saline (PBS), new medium was applied and the culture was maintained until day 7.
Patent derived EPCs cultured for 7 days were incubated with fuorescein isothiocyanate conjugated 3,3,3939-tetramethylindocar-bocyanine perchlo-rate (Dil)-labeled acetylated low density lipoprotein (Dilwere detected with a confocal microscope (Leica Microsystems GmbH, Germany). Dual-stained cells positive cultured for 7 days were used for subsequent experiments. 
EPC proliferation assay
Lentiviral Constructs, Packaging, and Transduction
To obtain stable expression of miR-130a and MAP3K12 in EPCs, human genomic DNA was used to sites, and the MAP3K12 PCR products were cloned into the plasmid pCDH-EF1-MCS-T2A-puro (System sequencing. For lentivirus production, the two plasmids were individually transfected into 293T cells using manufacturer's protocol. The medium was refreshed after 6 h, and viral supernatant was collected after 48 h. EPCs were seeded into 6-well plates (5×10 5 cells per well) and transfected with different lentiviral vectors
Luciferase reporter assay
The forward and reverse oligonucleotides of MAP3K12-Wt were annealed to form a segment sites. Similarly, a MAP3K12-Mut construct with a mutated targeting site transfection.
RNA extraction and real-time quantitative PCR
instructions (Qiagen, Germany). RNA was reverse transcribed to cDNA using PrimeScript RRT Master Mix 130a were measured using TaqMan real-time PCR and reactions were performed using a Roche Light Cycler
Western blot analysis
blotting was performed using primary antibodies against glyceraldehyde 3-phosphate dehydrogenase
Flow cytometry
TUNEL Assay
The apoptotic ability of EPCs was evaluated using terminal deoxynucleotidyl transferase-mediated
Colony-forming assay
The colony-forming capacity of EPCs was determined as previously described [16] . Isolated EPCs were 6 EPCs were seeded onto -well plates. After two days, the non-adherent cells were collected and 1×10 6 cells were a central core of rounded cells surrounded by elongating and spindle-shaped cells were counted.
Migration assay
resuspended in serum-free EBM medium and 4×10 4 cells were loaded into the upper chambers. The lower 
MAP3K12 is a target of miR-130a in EPCs
Computational target prediction was performed to identify relevant functional targets of version with a mutated binding site was also constructed. The vectors miR-130a or miRactivity was unaffected by miR-control with mutated nucleotides in the miR-130a seed binding site. Meanwhile, miR-130a-mediated repression of luciferase activity was abolished by the mutant putative binding site of the MAP3K12-Mut (Fig. 3B) . Western blot analysis showed that MAP3K12 expression was higher in EPCs derived from DM patients (0.93 ± p<0.05) (Fig.  3C ). To further verify our hypothesis, the expression levels of miR-130a were assessed in normal EPCs transfected with a lentivirus carrying miR-130a or miR-control, which showed (p<0.05 vs miR-control group) (Fig. 3D) , demonstrating that miR-130a was successfully (Fig. 3E) .
Inhibition of miR-130a and increase of MAP3K12 impair EPC function
To investigate the role of miR-130a in EPC function via its target MAP3K12, cells were transfected as follows: 1) EPCs derived from healthy donors were transfected with (a) empty vector as control, (b) lenti-miR-130a to overexpress miR-130a, (c) lenti-MAP3K12 to overexpress the MAP3K12 protein, (d) anti-miR-130a to decrease endogenous miRdiabetes patients were transfected with (a) empty vector as control, (b) lenti-miR-130a for recovery of miR-130a level, (c) MAP3K12-siRNA to decrease the elevated MAP3K12 protein level, (d) anti-miR-130a to inhibit relative miR-130a expression or (e) lenti-MAP3K12 to miR-130a group in normal EPCs to mimic the situation in diabetic EPCs (P<0.05 vs. control) (Fig. 4A) . The expression of MAP3K12 was altered depending on the different treatments as follows: in normal EPCs, MAP3K12 levels were decreased by overexpression of miR-130 or siRNA knock-down of MAP3K12, whereas they were increased by downregulation of miR- (Fig. 4B, 4C) . Meanwhile, the overexpression of either miR-130a or MAP3K12-siRNA also similarly decreased the MAP3K12 protein level in diabetic EPCs (P<0.05 vs. control) (Fig. 4B, 4C ). We also overexpressed the MAP3K12 or downregulated miR-130a in diabetic EPCs to further increase the MAP3K12 protein level in diabetic EPCs (P<0.05 vs. control) (Fig. 5A , 5B, 5C).
formation but reduced the apoptosis in diabetic EPCs (P<0.05 vs. control) (Fig. 4D, 4E, 4F ).
migration and colony formation and increased apoptosis in both normal and diabetic EPCs (P<0.05 vs. control) (Fig. 4D, 4E , 4F, 5D, 5E, 5F)
MiRNA-130a potentially impairs EPC function through the JNK pathway
transfected into healthy donor-derived EPCs to knock down miR-130a expression, and antimiR-1 was transfected into normal EPCs as control. Diabetic EPCs were transfected with control siRNA or MAP3K12 siRNA to knock down MAP3K12 expression. The protein levels measured by western blotting (Fig. 6A) . Normal EPCs treated with anti-miR-130a showed P<0.05 vs. control) (Fig. 6C, 6D, 6E ). In addition, in diabetic EPCs, Bcl-2 protein levels were 
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry lower than those in normal EPCs, and the level of cleaved caspase-3 was higher (P<0.05) (Fig. 6F, 6G ). However, down regulation of miR-130a in normal EPCs decreased Bcl-2 level and increased the cleavage of caspase-3, whereas down regulation of MAP3K12 in diabetic EPCs had the opposite effect (P<0.05 vs. control) (Fig. 6F, 6G ).
or apoptosis related protein levels (Fig. 7A) . Normal EPCs treated with MAP3K12 siRNA P<0.05 vs. control) (Fig. 7B, 7C, 7D, 7E) . Downregulation of miR-130a by anti-miR-130a in diabetic (P<0.05 vs. control) (Fig. 7B, 7C, 7D, 7E) . Meanwhile, downregulation of MAP3K12 in normal EPCs further increased Bcl-2 level and decreased the cleavage of caspase-3, whereas downregulation of miR-130a in diabetic EPCs further decreased the Bcl-2 but promote more cleavage of caspase-3 (P<0.05 vs. control) (Fig. 7F, 7G ).
Discussion
two to four-fold increased risk of cardiovascular diseases, and patients with pre-diabetic conditions, such as impaired fasting glucose and impaired glucose tolerance, are at increased step of the adverse sequence of events that leads to the atherosclerotic process [18, 19] . This is generally attributed to the adverse effects of hyperglycemia and oxidative stress on vascular biology. High glucose induces apoptosis through the activation of stress-activatedEPCs [5] . However, the mechanism regulating its upstream activation under high glucose conditions remains unclear.
MiRNA dysregulation has been observed in various pathological processes, including the EPC-mediated pathogenesis of diabetic complications. We screened miRNAs showing alterations in EPCs derived from type II DM patients and found that miR-130a was that the low level of miR-130a in diabetic EPCs may be involved in the functional impairment of EPCs in these patients.
MiR-130a appears to be widely expressed in diverse cell types and it regulates various Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry on the expression of miR-130a, normal EPCs were cultured under high glucose conditions (33 mmol/L) to mimic the diabetic microenvironment. It was shown that EPC proliferation also found that miR-130a was downregulated under high glucose and induced cell apoptosis. These results suggested a possible relationship between the downregulation of miRNA-130a and EPC apoptosis.
as a potential target of miR-130a in EPCs. MAP3K12 phosphorylates and activates the molecular mechanism underlying miR-130a-mediated effects by focusing on the role of decreased proliferation ability of diabetic EPCs could be high-glucose-induced miR-130a dependent apoptosis of EPCs and impaired EPC function.
To verify our hypothesis, we performed a luciferase reporter assay to demonstrate that and overexpression of miR-130a in EPCs dramatically decreased the mRNA and protein expression levels of MAP3K12. Functional assays showed that diabetic EPCs had impaired function compared to normal EPCs, which appeared to be partly associated with the downregulation of miR-130a and the effect on its targets MAP3K12. Inhibition of miR-130a migration and colony formation and increased apoptosis in EPCs, compared to the negative control. These results suggested that miR-130a is fundamental for the maintenance of normal EPC function by targeting MAP3K12.
To verify the results of the gain-of-function study, we further explored whether the involvement of miR-130a in EPC function was mediated by the regulation of the expression level of MAP3K12 in diabetic EPCs. In cells transfected with either lenti-miR-130a or the colony formation and migration capacity of EPCs was increased and apoptosis was decreased. These initial experiments suggested that miR-130a may negatively regulate viability of EPCs.
effect, lenti-miR-130a or anti-miR-130a was transfected into EPCs to regulate the level of expression and increase the levels of cleaved-caspase-3. Several studies have shown that the anti-apoptotic proteins Bcl-2 and Bcl-X L function is inhibited [23] [24] [25] . Bcl-2 proteins are known to regulate the release of mitochondrial cytochrome c and other mitochondrial pro-apoptotic molecules, which converge on the signaling in mitochondria include the pro-apoptotic BH 3 -only members (Bad, Bmf, Bim), radiation [26] [27] [28] . It has been also reported that the pro-apoptotic protein Bax/Bak may be , H2AX, a histone H2A variant, mediate apoptosis [32] . In the present study, prolonged downregulation of miR-130a under Fig. 8 ) [23] . In summary, the present study demonstrated that miR-130a is dysregulated in the EPCs of patients with DM. We showed that miR-130a plays an important role in impairing provide targets for strategic therapeutic applications in diabetes mellitus.
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